Modular Medical Receives IRB Approval to Deliver Insulin Using Pivot Patch Pump
Rhea-AI Summary
Modular Medical (NASDAQ:MODD) announced IRB approval on November 17, 2025 to run an in-house study delivering insulin with its next-generation Pivot™ tubeless patch pump to adult participants wearing continuous glucose monitors.
The Study will simulate real-world conditions to collect device function, usability data, and participant feedback while the company awaits FDA feedback on a recent Pivot 510(k) submission. The Pivot system is not currently cleared for sale by the FDA.
Positive
- IRB approval to deliver insulin to adult testers (Nov 17, 2025)
- Study will collect real-world device function and usability data
- Product targets a $3 billion adult "almost-pumpers" diabetes market
Negative
- Pivot not cleared for sale by the FDA
- Study results and commercial timing depend on pending FDA 510(k) feedback
News Market Reaction 4 Alerts
On the day this news was published, MODD declined 2.63%, reflecting a moderate negative market reaction. Argus tracked a peak move of +12.6% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $796K from the company's valuation, bringing the market cap to $29M at that time.
Data tracked by StockTitan Argus on the day of publication.
Study to Deliver Insulin to Internal Testers Wearing Continuous Glucose Monitors
SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology targeting the
Modular Medical's Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion.
Key objectives and potential impacts of the Study include:
Assess usability and the patient experience
Collect participant feedback to optimize design for everyday diabetes management
"This IRB approval marks another important milestone in advancing our tubeless insulin pump technology toward market readiness," said Jeb Besser, CEO of Modular Medical. "We now have approval to gather real-world data delivering insulin to adult test subjects in a controlled environment, as we await FDA feedback on our recent Pivot 510k submission. Once FDA clearance is achieved, we believe our Pivot pump will be well positioned to achieve rapid adoption in the growing wearable diabetes technology sector."
The Pivot insulin delivery system is not currently cleared for sale by the FDA.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the performance of the Company's products; expected deployments of the Company's pump products to persons with diabetes; the Company's ability to convert patients to use its pump products; the occurrence of future events or circumstances; successful development of Modular Medical's proprietary technologies; whether the market will accept Modular Medical's products and services; anticipated consumer demand for the Company's products; whether Modular Medical can successfully manufacture its products at high volumes; and general economic, industry and political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.
About Modular Medical
Modular Medical, Inc. (Nasdaq:MODD) is a medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
Pivot is a trademark of Modular Medical. All other trademarks mentioned herein are the property of their respective owners.
CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com
SOURCE: Modular Medical, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Modular Medical (MODD) announce on November 17, 2025?
What will the MODD Pivot study measure and why does it matter?
Is the Pivot pump cleared by the FDA for sale (MODD)?
How does the MODD study relate to the company’s 510(k) submission?
What market does Modular Medical (MODD) target with Pivot?
